Rodman & Renshaw Initiates Coverage On Hemab Therapeutics Hldgs with Buy Rating, Announces Price Target of $56

Benzinga Newsdesk www.benzinga.com Positive 61.6%

Neg 0% Neu 0% Pos 61.6%

Rodman & Renshaw analyst Michael G. King Jr. initiates coverage on Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Buy rating and announces Price Target of $56.